Accéder au contenu
Merck
Toutes les photos(4)

Principaux documents

SAB4200866

Sigma-Aldrich

Anti-Pseudomonas aeruginosa antibody produced in rabbit

IgG fraction of antiserum

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
12352203
Nomenclature NACRES :
NA.41

Source biologique

rabbit

Niveau de qualité

Forme d'anticorps

IgG fraction of antiserum

Type de produit anticorps

primary antibodies

Forme

liquid

Espèces réactives

Pseudomonas aeruginosa

Conditionnement

pkg of 100 μL
pkg of 25 μL

Concentration

~1 mg/mL

Technique(s)

immunoblotting: 1:10,000-1:20,000 using P.aeruginosa lysate
indirect ELISA: 1:5000- 1:0,000 using whole dead P.aeruginosa bacteria for coating

Conditions d'expédition

dry ice

Température de stockage

−20°C

Modification post-traductionnelle de la cible

unmodified

Description générale

Pseudomonas aeruginosa is a rod shaped, gram negative, monoflagellated, aerobic to facultative anaerobe bacteria which commonly inhabits soil and aqueous environments.1,2 P.aeruginosa is considered an opportunistic human pathogen mainly causing disease in immunocompromised patients. It is especially fatal in cystic fibrosis (CF) patients, but also presents a major problem in chronic wounds, burn wounds and infection of implanted biomaterials such as catheters.3P. aeruginosa is a major cause of nosocomial infections which affect more than 2 million
patients every year and are accounted for around 90,000 deaths annually.3
It forms highly resistant biofilms on human tissues such as the lungs of CF patients or medical surfaces. Once P. aeruginosa infection is established it is extremely hard to eradicate.3
The genome of P. aeruginosa encodes a vast arsenal of virulence factors. However, the P. aeruginosa isolated from chronic infections expresses less virulence factors in comparison to isolates from acute infections but more readily form biofilms.1,4-6

Spécificité

Anti-P. aeruginosa antibody recognizes P. aeruginosa whole dead bacteria and lysate, the antibody has no cross reactivity with whole dead bacteria or lysate of Proteus mirabilis, Porphyromonas gingivalis, E. coli, Shigella flexneri, Enterococcus faecalis, Akkermansia muciniphila or Salmonella enterica.

Application

The antibody may be used in various immunochemical techniques including Immunoblotting and ELISA. Detection of the P. aeruginosa bands by Immunoblotting is specifically inhibited by the immunogen.

Actions biochimiques/physiologiques

P. aeruginosa cells possess a single flagellum and type 4 pili that are important for adhesion to the host epithelial cells, motility and can also initiate an inflammatory response.1 After adhesion, P. aeruginosa activates Type 3 secretion system (T3SS) and injects cytotoxins into the host cell.1 Moreover, P. aeruginosa secretes several proteases, which can degrade host complement, mucins, and disrupt tight junctions6-7,. In addition to lipases and phospholipases, that degrade lipids in host cell membranes6, and expresses Lipopolysaccharide (LPS), that is involved in inflammatory response and antibiotic resistance8.

Antibiotic resistance to many classes of antibiotics is a major challange in P. aeruginosa treatment. P. aeruginosa possesses several resistance mechanisms such as, low permeability of the outer membrane,
expression of membrane efflux (Mex) pumps, and ß-lactamase and AmpC that hydrolases ß-lactam antibiotics such as, penicillin9. In addition, as a result of genetic transfer new resistant strains emerge constantly. Therefore, finding new prevention and treatment strategies for P. aeruginosa infection is of high importance.1

Forme physique

Supplied as a solution in 0.01 M phosphate buffered saline pH 7.4, containing 15 mM sodium azide as a preservative.

Stockage et stabilité

For continuous use, store at 2-8°C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.

Clause de non-responsabilité

Unless otherwise stated in our catalog  our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Code de la classe de stockage

12 - Non Combustible Liquids

Classe de danger pour l'eau (WGK)

WGK 1


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Alexander J Laarman et al.
Journal of immunology (Baltimore, Md. : 1950), 188(1), 386-393 (2011-12-02)
The complement system rapidly detects and kills Gram-negative bacteria and supports bacterial killing by phagocytes. However, bacterial pathogens exploit several strategies to evade detection by the complement system. The alkaline protease (AprA) of Pseudomonas aeruginosa has been associated with bacterial
Tanya Strateva et al.
Journal of medical microbiology, 58(Pt 9), 1133-1148 (2009-06-17)
Pseudomonas aeruginosa is one of the leading nosocomial pathogens worldwide. Nosocomial infections caused by this organism are often hard to treat because of both the intrinsic resistance of the species (it has constitutive expression of AmpC beta-lactamase and efflux pumps
Eric E Smith et al.
Proceedings of the National Academy of Sciences of the United States of America, 103(22), 8487-8492 (2006-05-12)
In many human infections, hosts and pathogens coexist for years or decades. Important examples include HIV, herpes viruses, tuberculosis, leprosy, and malaria. With the exception of intensively studied viral infections such as HIV/AIDs, little is known about the extent to
Jerry D King et al.
Innate immunity, 15(5), 261-312 (2009-08-28)
Pseudomonas aeruginosa causes serious nosocomial infections, and an important virulence factor produced by this organism is lipopolysaccharide (LPS). This review summarizes knowledge about biosynthesis of all three structural domains of LPS - lipid A, core oligosaccharide, and O polysaccharides. In
D J Hassett
Journal of bacteriology, 178(24), 7322-7325 (1996-12-01)
Pseudomonas aeruginosa produced alginate and elevated algD (encoding GDPmannose 6-dehydrogenase) transcription under strict anaerobic conditions, especially when using nitrate as a terminal electron acceptor. Purified alginate added to bacterial suspensions caused a decrease in growth, suggesting that alginate contributes to

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique